Completed

Oral Retrovir Pharmacokinetics in HIV Patients with Severe Manifestations

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Zidovudine

Drug
Who is being recruted

Blood-Borne Infections+14

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+31 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study is about finding the best dosage frequency for a drug called Retrovir (AZT) in treating patients with severe symptoms of HIV infection, including AIDS or severe ARC. The goal is to understand how the body responds to different doses of Retrovir, which could help improve treatment for these patients by making it more effective and safer. The study focuses on individuals suffering from serious HIV-related health issues, aiming to address their unmet medical needs.

NCT00002046
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections

Criteria

12 inclusion criteria required to participate
Chronic diarrhea of unknown infectious etiology persisting > 1 month after 3 samples have been done eliminating ova, parasites, Cryptosporidia, Mycobacterium avium intracellulare, cytomegalovirus (CMV), and other pathogens associated with diarrheal disease in AIDS patients
Fever > 38 degrees C, without documented infectious cause present, persisting > 1 month
Herpes zoster infection within 3 months of entry
History of Pneumocystis carinii pneumonia (PCP) with histologic verification within 4 months of study entry
Show More Criteria
19 exclusion criteria prevent from participating
AIDS dementia complex
Active drug or alcohol abuse
Acyclovir therapy of more than 21 days duration
Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine, didanosine, foscarnet, dextran sulfate, and AL-721
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 11 locations

Univ of Arizona / Health Science Ctr

Tucson, United StatesOpen Univ of Arizona / Health Science Ctr in Google Maps

Northwestern Univ Med School

Chicago, United States

Cook County Hosp

Chicago, United States

Rush Presbyterian - Saint Luke's Med Ctr

Chicago, United States
Completed11 Study Centers